Research project Exploring the role of a non-coding oligonucleotide to dampen skin inflammation and itch
![Illustrerande bild över forskningen](/polopoly_fs/1.737433.1716213919!/image/image.jpg_gen/derivatives/widescreen_690/image.jpg)
Skin-resident antigen-presenting cells play an important role in maintaining peripheral tolerance via immune checkpoint proteins and induction of T regulatory cells (Tregs). However, we lack knowledge on how to expand or recruit immunoregulatory cutaneous cells without causing inflammation. We have found that administration of a non-coding single-stranded oligonucleotide (ssON) leads to CCR2-dependent accumulation of CD45+CD11b+Ly6C+ cells in the skin that express substantial levels of the immunological checkpoint proteins PD-L1 and ILT3 in mice. Functionally, the cutaneous CD11b+ cells inhibited Th1/2/9 responses and promoted the induction of CD4+FoxP3+ Tregs. In addition, ssON treatment of imiquimod-induced inflammation resulted in significantly reduced Th17 responses. We have also conducted a multicenter randomized (1:1), double-blinded, placebo-controlled study in 52 client-owned dogs with mild-moderate atopic dermatitis. Treatment with the immune-modifying oligonucleotide showed significant clinical benefit over placebo with rapid onset of treatment effect, durable improvements, and a good field safety profile. Altogether, we have identified an immunomodulatory ssON that can be used therapeutically to dampen Th cells and ameliorate itch as well as induce long-term effects. Our current studies focus on revealing the immunological mechanisms governing the long-term treatment results.
Project members
Project managers
Anna-Lena Spetz
Professor
![Photo: Eva Dalin/Stockholm University Anna-Lena Spetz](/polopoly_fs/1.612460.1652689671!/image/image.jpg_gen/derivatives/box_260/image.jpg)
Members
James Trumbo
Phd Student
![Foto: Sören Andersson James Trumbo](/polopoly_fs/1.696266.1701691660!/image/image.jpg_gen/derivatives/box_260/image.jpg)
Kahkashan Kamal
PhD student